Clinical Trial

HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study investigates the first-line treatment of advanced pancreatic cancer with KRAS G12D mutation. Patients were randomized 1:1 to receive either the experimental regimen HRS-4642 plus AG or the control regimen AG alone.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-14.
Status change: Not Yet Recruiting → Recruiting 2026-07-14
Trial Details
NCT Number NCT07232875
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting
Enrollment 588 participants
Start Date 2025-11-21
Primary Completion 2029-04 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-15